Skip to main content
TipRanks
Go Ultimate75% OFF

BioLargo (BLGO) AI Stock Analysis

70 Followers
BLGO

BioLargo

(Other OTC:BLGO)

Select Model
Rating:40Underperform
Price Target:$0.07â–²(0.00% Upside)
Action:reiterated
Date:11/03/26

The overall score of 40 reflects a company in significant financial distress, with negative equity, steep operating losses, and high cash burn. While the earnings call and recent corporate events point to multiple potential growth catalysts in wound care, PFAS, and consumer products, these initiatives are early-stage and unproven. The stock's weak technical position and negative valuation metrics reinforce the high-risk profile. The most significant factors are the severe financial deterioration and negative equity, which overshadow the promising but uncertain commercial developments.

Positive Factors
Core engineering revenue growthGrowth in the engineering business provides a durable operating foundation because it is tied to third-party environmental customers rather than only one emerging product. Management’s description of the business as growing and stable supports the potential for recurring service-led revenue and improved scale.
Negative Factors
Shrinking revenue and severe operating lossesThe revenue contraction and exceptionally negative operating margins show that the current cost structure remains far ahead of the business’s sales base. Unless commercialization produces sustained growth, continued losses can constrain investment, weaken operating leverage, and increase dependence on external capital.

BioLargo (BLGO) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%BLGO-55.26%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$22.76M
Dividend Yield
―
Average Volume (3M)
438.38K
Price to Earnings (P/E)
-1.5
Beta (1Y)
-0.05
Revenue Growth
-70.95%
EPS Growth
-257.36%
Country
US
Employees
45
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

BioLargo Business Overview & Revenue Model

Company Description

BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination...

How the Company Makes Money

BioLargo generates revenue primarily through a combination of (1) product and technology commercialization and (2) service/engineering activities tied to environmental solutions. Product-driven revenue can include sales of odor/VOC control products a...

BioLargo Earnings Call Summary

Earnings Call Date:Aug 17, 2026(Q2-2026)|% Change Since:-34.62%|Next Earnings Date:May 19, 2021
Earnings Call SentimentPositive

The call was strongly forward-looking and optimistic, emphasizing revenue growth in the core engineering business, multiple distribution channels for Clyra, PFAS commercial progress, new ventures, and potential contract opportunities. However, management also acknowledged a difficult year marked by a market capitalization decline of more than 60%, the loss of the Pooph business, a close to $4 million write-down, Clyra’s launch delay and burn rate, and ongoing financing and regulatory uncertainty. The number and strength of the stated achievements and initiatives outweighed the stated challenges.

Positive Updates

Core Engineering Business Revenue Growth
Quarter-to-quarter revenue increased, with growth driven by the engineering group’s increased sales to third-party customers. The remainder of the products and services provided by ONM also increased, and management described the core business as growing and stable.

Negative Updates

Market Capitalization Decline
Management stated that BioLargo’s market capitalization declined by well over 60%, approaching 70%, during the prior year.

Company Guidance

Management expects to launch the consumer products category in the October time frame, with a conservative target of about half the numbers that Pooph generated, realistically coming in the $15-plus million range over the first course of a year to 1.5 years; Clyra’s national distribution launch is targeted for 2027 start, with a 3- to 6-month setup, while its 3 active distributors encompass probably 70-plus percent of the market. Cellinity’s strategy involves factories with about $250 million of CapEx, factories of about $170 million each, incentives as much as 50% of CapEx, and a Puerto Rico project where 80-plus percent of the project can get financed with incentives; its design targets 10 years, no degradation and another 10-year cycle with only 4% degradation, versus a 7-year market with up to 15% degradation. The minerals facility is expected to move to Phase 2, probably somewhere around the $10 million range, take about a year, 1.5 years, and potentially lead to a design build probably something in the $40 million range; water projects being scoped include $5 million, $10 million, $25 million and $30 million projects, including systems of 3 million gallons a day, with a proposed 80% reduction in OpEx. A multimillion-dollar military grant is hoped to get funded in Q1, and the annual meeting target is December 1.

BioLargo Financial Statement Overview

Summary

Financial performance is critically weak. TTM revenue declined 27% YoY, operating loss margin is -352%, and net losses widened to $14.5M. The balance sheet shows negative equity of -$1.85M, and operating cash flow is deeply negative at -$10.3M, indicating severe liquidity and solvency risks.

Income Statement

12Very Negative

Balance Sheet

5Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue4.08M7.76M17.78M12.23M5.88M2.53M
Gross Profit1.63M3.41M7.85M6.15M2.86M1.10M
EBITDA-17.74M-14.55M-4.06M-4.27M-5.10M-6.70M
Net Income-14.48M-11.78M-2.40M-3.50M-4.50M-7.38M
Balance Sheet
Total Assets6.67M8.31M10.51M8.21M4.86M3.02M
Cash, Cash Equivalents and Short-Term Investments2.19M3.88M3.55M3.54M1.85M962.00K
Total Debt6.39M3.51M2.55M1.70M1.47M1.13M
Total Liabilities9.40M6.79M4.46M4.00M2.85M2.09M
Stockholders Equity-1.85M4.04M8.85M6.84M4.88M4.65M
Cash Flow
Free Cash Flow-10.37M-8.34M-4.44M-2.84M-3.03M-3.97M
Operating Cash Flow-10.32M-8.30M-3.21M-2.37M-2.76M-3.94M
Investing Cash Flow51.00K435.00K-1.32M-478.00K-271.00K-34.00K
Financing Cash Flow8.99M8.22M4.44M4.66M3.96M4.23M

BioLargo Technical Analysis

Technical Analysis SentimentNegative
Last Price0.07

Price Trends

50DMA0.08Negative
100DMA0.09Negative
200DMA0.12Negative

Market Momentum

MACD-0.00Negative
RSI44.73Neutral
STOCH37.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 44.73 is Neutral, neither overbought nor oversold. The STOCH value of 37.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.

BioLargo Risk Analysis

BioLargo disclosed 44 risk factors in its most recent earnings report. BioLargo reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.Increased information technology security threats and more sophisticated computer crime pose a risk to us and our subsidiaries, vendors, systems, networks, products and services.Q4, 2023
2.Our business involves the use, transmission and storage of confidential information, and the failure to properly safeguard such information could result in significant reputational harm.Q4, 2023

BioLargo Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

BLGO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
FFFF53Neutral$124.13M-4.26-19.93%4.83%71.16%14.82%
ASIXASIX49Neutral$425.12M-18.67-2.84%4.08%8.37%-142.98%
TROXTROX41Neutral$418.43M-0.83-40.46%7.63%11.85%-55.06%
BLGOBLGO40Underperform$22.69M-1.50-548.88%―-70.95%-257.36%
RYAMRYAM39Underperform$370.69M-1.04-207.27%―1.62%12.68%

* Basic Materials Sector Average

Performance Comparison

0%100%200%BLGOFFTROXRYAMASIXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BLGO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BLGOBioLargo 0.07-0.09-56.41%
FFFuturefuel2.90-0.23-7.50%
TROXTronox2.62-0.44-14.27%
RYAMRayonier Advanced Materials5.650.132.36%
ASIXAdvanSix15.681.7812.77%

BioLargo Corporate Events

Business Operations and StrategyProduct-Related Announcements

BioLargo Reports Commercial Traction for ViaCLYR Wound Solution

Positive
Nov 2, 2026

On November 2, 2026, BioLargo said its subsidiary Clyra Medical had gained commercial traction for ViaCLYR, an FDA 510(k)-cleared wound irrigation solution, following the Fall 2026 Symposium on Advanced Wound Care. Since its March 2026 commercial lau...

Business Operations and StrategyRegulatory Filings and Compliance

BioLargo Highlights Investor Presentation and Disclosure Practices

Neutral
Sep 11, 2026

On September 10, 2026, BioLargo, Inc. presented a slide deck at a webcast investor conference, and subsequently furnished those materials to the U.S. Securities and Exchange Commission in a Current Report on Form 8-K. The company emphasized that the...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026